Minocycline HCl
€19.00 – €89.00
Minocycline hydrochloride powder
SKU: minocycline-hcl
ACTIVE INGREDIENT: Minocycline hydrochloride
ADDITIONAL INGREDIENTS: –
OTHER NAMES: KlinoMycin, Minocycline chloride, MinoMycin, NSC 141993;(4S,4aS,5aR,12aS)-4,7-Bis(diMethylaMino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxaMide hydrochloride; 2-Naphthacenecarboxamide, 4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, hydrochloride (1:1), (4S,4aS,5aR,12aS)-;
CAS NUMBER: 13614-98-7
ATC CODE: A01AB23; D10AF07; J01AA08;
FORMULA: C23H27N3O7 · HCl
MOLAR MASS: 493.94 g·mol−1
ITEM TYPE: powder
QUANTITY PER PACK: 1 gram and 5 grams
STORAGE: Store in a cool and dry place. Keep away from direct sunlight and heat. Keep out of reach of children.
A micro spoon is added to Minocycline HCl (blue) = 50 mg (approximately).
The product is not intended for human use. For laboratory use only.
Minocycline has been studied for treatment-resistant depression. According to a 2023 systematic review based on four clinical trials, “There is no significant difference with minocycline compared to placebo for depression not responding to first-line antidepressant therapy.”
Early research has found a tentative benefit from minocycline in schizophrenia, with several trials underway. A 2014 meta-analysis found minocycline may reduce negative and total symptom scores and was well tolerated.
Some early studies suggest that minocycline may be beneficial as an add-on treatment for moderate-to-severe obsessive-compulsive disorder (OCD) when used with an SSRI.
In ongoing research and trial, minocycline demonstrated efficacy and seems a promising neuroprotective agent in acute stroke patients, especially in AIS subgroup. Further RCTs are needed to evaluate the efficacy and safety of minocycline among ICH patients.
Research is examining the possible neuroprotective and anti-inflammatory effects of minocycline against the progression of a group of neurodegenerative disorders including multiple sclerosis, rheumatoid arthritis, Huntington’s disease, and Parkinson’s disease. As mentioned above, minocycline harms ALS patients.
Several preclinical studies (in vitro cell cultures and animal models) suggest that minocycline may have otoprotective benefits. Animal models indicate it could potentially reduce noise-induced and blast-induced hearing loss, possibly by protecting hair cells and mitigating inflammation. In vitro and animal studies also show minocycline may help decrease ototoxicity from certain drugs like gentamicin, neomycin, and cisplatin.